Health News

Sage, Biogen's drug meets main goal in postpartum depression study

Sage, Biogen's drug meets main goal in postpartum depression study
FILE PHOTO: A sign marks a Biogen facility in Boston, U.S., March 9, 2020. REUTERS/Brian Snyder

(Reuters) – Sage Therapeutics Inc and Biogen’s experimental drug showed improvement in depressive symptoms among women with postpartum depression at day 15, meeting the main goal of a late-stage study, the companies said on Wednesday.

Source: Read Full Article

Related posts:
  1. The FDA may approve a COVID-19 vaccine before trials are complete. Here’s what you need to know
  2. Novel diabetes subgroups show differences in biomarkers of inflammation
  3. Research on psychedelics could lead to new treatments for mental illness
  4. Covid: What are your chances of getting it again? Study finds odds of reinfection